The eGFR levels were higher for the everolimus group through the study but the treatment comparisons did not show any statistically significant differences between the groups at any time point (Table 4; see also Additional file 2).
everolimus regimen
mycophenolate mofetil (MMF) regimen
combined rate of death, graft loss and LTFU at month 12